GV's David Schenkein comes in to help mentor — and bankroll — a gene therapy 2.0 player, intrigued by their ‘science heavy’ approach to conquering severe disease
A year ago, Encoded Therapeutics burst on the scene with a $104 million mega-raise that spotlighted their work on gene therapy 2.0 — focused on breaking through the boundaries of AAV gene therapy in beating Dravet syndrome.
And now they’re back with an even bigger raise that includes financial backing from GV’s David Schenkein after rounding out an impressive executive team with some of the top experts in the field, including some old allies of ex-AveXis CEO Sean Nolan, an investor and chairman/godfather who would like to be in on the birth of newer and better gene therapies that can trample down some of the tech hurdles that limit gen-one.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,800+ biopharma pros reading Endpoints daily — and it's free.